@article{0e9f6176c8f94feca4c3f4d5b2302f66,
title = "Patient-reported symptom severity, interference with daily activities, and adverse events in older and younger women receiving chemotherapy for early breast cancer",
abstract = "Background: To the authors' knowledge, it is unknown whether patient-reported symptom severity and symptom interference with daily activities differ between younger (aged <65 years) and older (aged ≥65 years) women receiving similar chemotherapy regimens for early breast cancer (EBC). Methods: Study participants rated 17 side effects of chemotherapy regimens currently in use in clinical practice (2014-2019). Results: Of 284 women with EBC (stage I-III), approximately 57% were aged <65 years and 43% were aged ≥65 years. For anthracycline-based regimens, a higher percentage of younger women reported moderate, severe, or very severe (MSVS) hot flashes (49% vs 18%) (P <.001). For nonanthracycline regimens, a higher percentage of younger women reported MSVS hot flashes (38% vs 19%) (P =.009) and a lower percentage reported MSVS arthralgia (28% vs 49%) (P =.005). With regard to symptom interference with daily activities, a higher percentage of younger women being treated with anthracycline-based regimens reported MSVS hot flashes (32% vs 7%) (P =.001) and myalgia (38% vs 18%) (P =.02). For nonanthracycline chemotherapy, a higher percentage of younger women reported MSVS interference for hot flashes (26% vs 9%) (P =.006) and lower percentages reported abdominal pain (13% vs 28%) (P =.02). Overall, there were no significant differences noted among younger versus older patients with regard to hospitalizations (19% vs 12%; P =.19), dose reductions (34% vs 31%; P =.50), dose delays (22% vs 25%; P =.59), or early treatment discontinuation (16% vs 16%; P =.9546). Conclusions: Older and younger women with EBC who were treated with identical chemotherapy regimens generally experienced similar levels of symptom severity, symptom-related interference with daily activities, and adverse events. Lay Summary: In this study, women receiving chemotherapy for early breast cancer rated the severity of 17 symptoms and symptom interference with their activities of daily living. Older (aged ≥65 years) and younger (aged <65 years) women who received identical chemotherapy regimens generally experienced similar levels of symptom severity, symptom-related interference with daily activities, and adverse events.",
keywords = "breast cancer, chemotherapy, interference, severity, side effects",
author = "Nyrop, {Kirsten A.} and Deal, {Allison M.} and Chen, {Yi Tang} and Reeve, {Bryce B.} and Basch, {Ethan M.} and Wood, {William A.} and Shachar, {Shlomit S.} and Carey, {Lisa A.} and Reeder-Hayes, {Katherine E.} and Dees, {E. Claire} and Jolly, {Trevor A.} and Kimmick, {Gretchen G.} and Karuturi, {Meghan S.} and Reinbolt, {Raquel E.} and Speca, {Jo Ellen C.} and Lee, {Jordan T.} and Addison Brenizer and Muss, {Hyman B.}",
note = "Publisher Copyright: {\textcopyright} 2020 American Cancer Society",
year = "2021",
month = mar,
day = "15",
doi = "10.1002/cncr.33329",
language = "אנגלית",
volume = "127",
pages = "957--967",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "6",
}
